Charles Schwab’s Harvard Bioscience HBIO Stock Holding History

Charles Schwab’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,888	Closed	-$56K	–	3524
2025 Q1	$56K	Sell	9,888 -14,082	-59%	-$180K	﹤0.01%	3392
2024 Q4	$506K	Hold	23,970	–	–	﹤0.01%	3137
2024 Q3	$645K	Hold	23,970	–	–	﹤0.01%	3065
2024 Q2	$683K	Buy	23,970 +992	+4%	+$34.8K	﹤0.01%	3063
2024 Q1	$974K	Sell	22,978 -690	-3%	-$31K	﹤0.01%	2807
2023 Q4	$1.27M	Hold	23,668	–	–	﹤0.01%	2760
2023 Q3	$1.02M	Buy	23,668 +644	+3%	+$29.7K	﹤0.01%	2792
2023 Q2	$1.26M	Buy	23,024 +7,890	+52%	+$433K	﹤0.01%	2691
2023 Q1	$636K	Hold	15,134	–	–	﹤0.01%	2878
2022 Q4	$419K	Sell	15,134 -4,546	-23%	-$112K	﹤0.01%	3047
2022 Q3	$504K	Hold	19,680	–	–	﹤0.01%	3000
2022 Q2	$709K	Sell	19,680 -6,939	-26%	-$313K	﹤0.01%	2924
2022 Q1	$1.65M	Buy	26,619 +5,632	+27%	+$333K	﹤0.01%	2712
2021 Q4	$1.48M	Hold	20,987	–	–	﹤0.01%	2786
2021 Q3	$1.47M	Buy	20,987 +321	+2%	+$25.5K	﹤0.01%	2764
2021 Q2	$1.72M	Buy	20,666 +11,117	+116%	+$786K	﹤0.01%	2764
2021 Q1	$522K	Buy	9,549 +696	+8%	+$33.9K	﹤0.01%	3066
2020 Q4	$380K	Hold	8,853	–	–	﹤0.01%	3078
2020 Q3	$267K	Hold	8,853	–	–	﹤0.01%	3073
2020 Q2	$275K	Buy	+8,853	New	+$239K	﹤0.01%	3081
2019 Q4	–	Sell	-10,942	Closed	-$337K	–	3180
2019 Q3	$337K	Hold	10,942	–	–	﹤0.01%	2941
2019 Q2	$219K	Buy	10,942 +3,425	+46%	+$100K	﹤0.01%	3074
2019 Q1	$324K	Sell	7,517 -972	-11%	-$35.2K	﹤0.01%	2920
2018 Q4	$270K	Hold	8,489	–	–	﹤0.01%	2964
2018 Q3	$446K	Buy	8,489 +1,630	+24%	+$91.5K	﹤0.01%	2881
2018 Q2	$367K	Buy	6,859 +4,929	+255%	+$252K	﹤0.01%	2899
2018 Q1	$97K	Hold	1,930	–	–	﹤0.01%	3041
2017 Q4	$64K	Hold	1,930	–	–	﹤0.01%	3049
2017 Q3	$73K	Hold	1,930	–	–	﹤0.01%	3063
2017 Q2	$50K	Hold	1,930	–	–	﹤0.01%	3096
2017 Q1	$51K	Hold	1,930	–	–	﹤0.01%	3040
2016 Q4	$59K	Hold	1,930	–	–	﹤0.01%	3064
2016 Q3	$53K	Hold	1,930	–	–	﹤0.01%	3023
2016 Q2	$56K	Sell	1,930 -7,493	-80%	-$238K	﹤0.01%	3078
2016 Q1	$285K	Hold	9,423	–	–	﹤0.01%	2790
2015 Q4	$327K	Hold	9,423	–	–	﹤0.01%	2830
2015 Q3	$357K	Buy	9,423 +3,420	+57%	+$159K	﹤0.01%	2755
2015 Q2	$343K	Buy	6,003 +4,073	+211%	+$232K	﹤0.01%	2817
2015 Q1	$113K	Hold	1,930	–	–	﹤0.01%	3023
2014 Q4	$110K	Hold	1,930	–	–	﹤0.01%	3055
2014 Q3	$79K	Hold	1,930	–	–	﹤0.01%	3048
2014 Q2	$88K	Sell	1,930 -3,080	-61%	-$129K	﹤0.01%	3064
2014 Q1	$238K	Hold	5,010	–	–	﹤0.01%	2893
2013 Q4	$236K	Sell	5,010 -1,598	-24%	-$69.8K	﹤0.01%	2906
2013 Q3	$264K	Hold	6,608	–	–	﹤0.01%	2810
2013 Q2	$239K	Buy	+6,608	New	+$253K	﹤0.01%	2823

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's HBIO Position: Q2 2025 in Review

Charles Schwab sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 9,888 shares — an estimated $56K sold.

Charles Schwab first reported a position in HBIO in Q2 2013 and held it in 46 quarters. The position peaked at $1.72M in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

Charles Schwab reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
Charles Schwab sold 9,888 Harvard Bioscience shares in Q2 2025, an estimated $56K.
Charles Schwab first reported a position in Harvard Bioscience in Q2 2013 and held it in 46 quarters.
Charles Schwab's Harvard Bioscience position peaked at $1.72M in Q2 2021.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.